CPIXCumberland Pharmaceuticals Inc.
$7.44
$0.135
(1.85%)
EarningsAug 4
Mkt Cap$109.38M
Vol6,947.00
ELTP vs. CPIX: Which Pharma Stock Is the Better Buy Right Now?
Elite Pharmaceuticals and Cumberland Pharmaceuticals follow different growth paths, but which looks more compelling now? Let's dive in.
Zacks
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE
CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE PR Newswire NASHVILLE, Tenn., July 13, 2026 Record Date is July 10, 2026 & Payment Date is July 31,2026Corporate and Insider Share Purchase Initiatives...
PR Newswire
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex
Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex PR Newswire NASHVILLE, Tenn., July 1, 2026 $100 million Transaction Follows Cumberland Shareholder ApprovalStrengthens Cumberland's Focus on Rare Disease...
PR Newswire
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference
Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference Cumberland Pharmaceuticals Shares Updated FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference PR Newswire NASHVILLE, Tenn., June 26, 2026...
PR Newswire
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement PR Newswire TEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 $6 million upfront with up to approximately $13.4 million of potential aggregate...
PR Newswire
RedHill Biopharma Announces Up To $19.4 Million Private Placement
RedHill Biopharma Announces Up To $19.4 Million Private Placement RedHill Biopharma Announces Up To $19.4 Million Private Placement PR Newswire TEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 $6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the...
PR Newswire
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation PR Newswire RALEIGH, N.C. and...
PR Newswire
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 RALEIGH, N.C.and TEL-AVIV, Israel, June 8...
PR Newswire
Cumberland's Ifetroban Shows Potential to Limit Metastasis
CPIX reports positive Phase 2a results for Ifetroban, showing a favorable safety profile and promising early signs of reducing cancer metastasis in high-risk patients.
Zacks
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis PR Newswire NASHVILLE, Tenn., June 2, 2026 Positive Results from Phase 2a...
PR Newswire
<
1
2
...
>
